The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma
- 1 July 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 95 (1) , 66-71
- https://doi.org/10.1016/s1081-1206(10)61190-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Safety of Fluticasone propionate/Salmeterol Diskus® in Pediatric Patients Ages 4 –11 with AsthmaChest, 2004
- Balancing safety and efficacy in the treatment of pediatric asthmaJournal of Allergy and Clinical Immunology, 2002
- Salmeterol/fluticasone propionate (50/100 ?g) in combination in a Diskus? inhaler (Seretide?) is effective and safe in children with asthmaPediatric Pulmonology, 2000
- Efficacy of Salmeterol Xinafoate Powder in Children with Chronic Persistent AsthmaPublished by Elsevier ,1998
- Intranasal salmeterol inhibits allergen‐induced vascular permeability but not mast cell activation or cellular infiltrationClinical and Experimental Allergy, 1998
- Salmeterol inhibition of mediator release from human lung mast cells by β-adrenoceptor-dependent and independent mechanismsBritish Journal of Pharmacology, 1998
- Topical Salmeterol Reduces Protein Content of Nasal Lavage Fluid in Response to Allergen and Histamine Challenge: Double-Blind Cross-over Placebo-Controlled Studies in AdultsAmerican Journal of Rhinology, 1996
- Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skinBritish Journal of Pharmacology, 1992
- Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lungBritish Journal of Pharmacology, 1991
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987